About this trial
Thrombocytopenia is a common biological disorder in critically ill patients. The main supportive treatment is platelet transfusion with the aim of preventing and treating bleeding and securing invasive procedures. Current guidelines suggest that prophylactic platelet transfusion should probably be administered in non-bleeding critically ill patients at platelet count triggers of 10 to 20 G/L, albeit with very low certainty since extrapolated from studies carried out in stable patients with hematological malignancies. Indications for prophylactic platelet transfusion have not been properly addressed in adult ICU patients with regard to their particular risk of bleeding and prognosis. We propose the TRAMPOLINE study in order to address two different platelet count thresholds of 10 G/L (low threshold) or 20 G/L (high threshold) for the prevention of ICU-acquired bleeding in critically ill patients with severe thrombocytopenia.
Eligibility criteria
Qualifiers
Age ≥ 18 y.o. AND
Hospitalisation in the ICU with at least one of the following life support during the current ICU stay (past or ongoing, regardless of indications)
circulatory support (inotropes/ vasopressors at any dose)
respiratory support (invasive mechanical ventilation, non-invasive ventilation, continuous positive airway pressure (CPAP), high-flow nasal oxygen, O2 supply ≥ 6 L/min)
Disqualifiers
Major bleeding (WHO grade 3-4) or mild bleeding (WHO grade 2) within the present hospitalization
Major surgery within the recent 72 hours
Intracranial or retinal bleeding within the recent 7 days
Non- or contra-indication to prophylactic platelet transfusion (immune thrombocytopenia, thrombotic microangiopathy)
Trial design
Treatments tested in this trial
- Platelet transfusion if platelet count ≤ 10 G/L
- Platelet transfusion when platelet count ≤ 20 G/L